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Molecular information systems play an important part in modern data-driven drug discovery. They do
not only support decision making but also enable new discoveries via association and inference. In this
review, we outline the scientific requirements identified by the Innovative Medicines Initiative (IMI)
Open PHACTS consortium for the design of an open pharmacological space (OPS) information system.
The focus of this work is the integration of compound–target–pathway–disease/phenotype data for
public and industrial drug discovery research. Typical scientific competency questions provided by the
consortium members will be analyzed based on the underlying data concepts and associations needed to
answer the questions. Publicly available data sources used to target these questions as well as the need for
and potential of semantic web-based technology will be presented.
Introduction
Drug discovery is a data-driven process [1]. The amount and
diversity of drug discovery data in the omics- and high-through-
put-driven paradigms has significantly grown to the point where
current relational data models have reached their performance
limits in terms of technical and scientific capabilities [2]. In addi-
tion to the need for data integration, it is recognized that provid-
ing capabilities for semantic inference is a key challenge and offers
a wealth of opportunities. Such a semantic molecular information
system was pioneered by the Wild group at Indiana University
R
ev
ie
w
s
 I
N
F
O
R
M
A
T
IC
S
Corresponding author:. Ecker, G.F. (gerhard.f.ecker@univie.ac.at)
a Present address: ELIXIR, EMBL-European Bioinformatics Institute, Wellcome
Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK.
1359-6446/06/$ - see front matter  2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.drudis.2013.05.008 www.drugdiscoverytoday.com 843
with the Chem2Bio2RDF system [3–6], which is based on the
Bio2RDF knowledge system provided earlier by Belleau at Laval
University, Montreal [7]. The Linking Open Drug Data (LODD)
project [8] is a comparable project within the World Wide Web
Consortium (W3C) [9] healthcare and life science interest group.
Recognizing the challenges and opportunities, the European
Union (EU) and European Federation of Pharmaceutical Industries
and Associations (EFPIA) decided to develop the Innovative Med-
icines Initiative (IMI) joint undertaking, and through this [10] the
Open Pharmacological Concepts Triple Store (Open PHACTS)
consortium [11]. The Open PHACTS project brings together aca-
demic and pharmaceutical partners to design and implement a
publicly available open pharmacological space. The project is
driven by scientific questions and use cases of various complexity
that apply to real-world drugs that, for the purpose of the Open
PHACTS project, we term ‘scientific competency questions’. By
focusing on standard use cases for drug discovery, the importance
of the competency questions is reflected in their general nature
rather than in the specific questions per se. The seemingly straight-
forward questions provide model scenarios that require careful
association (mapping) of multiple heterogeneous data across
diverse public domain databases. Core underlying data concepts
for this medicinal-chemistry-driven platform are ‘compound’,
‘target’, ‘pathway’ and ‘disease/phenotype’, all of them are rele-
vant for the new fields of chemogenomics [12] and systems che-
mical biology [13,14].
As will become apparent from the analysis of the scientific
competency questions, the Open PHACTS system will build upon
the ideas of the Chem2Bio2RDF, Bio2RDF and LODD systems, to
address drug discovery research questions specifically. A key feature
of the Open PHACTS discovery platform is the openness for new
data additions that could include data from text mining of scientific
publications as well as opportunities for integration with proprie-
tary or commercial data sources. Another key aspect is the devel-
opment of novel visualization tools that facilitate the navigation
and knowledge extraction from all integrated data made available. It
is intended for the end-user tools not only to show how it is possible
to build relevant end-user applications on top of the Open PHACTS
platform but also to provide the bench scientist with immediate
value. Of course, all electronic data should be used with caution and
scientists need to be aware of its origin, provenance and reliability.
Thus, the goal in the Open PHACTS project is not simply to integrate
and query multiple databases but to provide a mechanism to under-
stand how these results were obtained with attribution and prove-
nance of individual data points [15].
A scientific competency question approach
When setting up an open, innovative, data integration and knowl-
edge extraction platform, the first question arising is which out of
the more than 1000 open access databases [16] need to be inte-
grated. This obviously depends on the type of queries the system
should allow the user to perform. Driven by the fact that in the first
instance the target audience will be bench scientists working in
drug discovery and development, the Open PHACTS consortium
develops a set of core use-cases to guide the project and to assist in
prioritizing the data sources selected for integration. Thus, the
original 22 Open PHACTS partners (eight EFPIA companies, 12
academic institutions, two SMEs; the project is continuously
growing and currently comprises 28 partners now already) were
asked to provide ‘business’ questions that they believed would
enable progress in their specific research activities and drug dis-
covery in general. Although most of the questions provided are not
challenging per se, answering them requires input from multiple
data sources hence needs in-depth knowledge of the data models
for a large set of systems. Thus, these represent a challenge to the
current information systems in use. Analysis of these questions
provides valuable information for the design of the graphical user
interface and guides the selection of data sources. In total 83
questions were collected in this approach, representing an effec-
tive survey of user needs and information priorities for preclinical
drug discovery research in pharmaceutical companies and aca-
demic institutions. The analysis of the questions followed a struc-
tured approach with input and critique from project partner
representatives. Because the results represent a clear and priori-
tized set of requirements and use cases for drug discovery research
projects, we believe they will have significant impact and use with
regard to knowledge management and systems design. The 83
questions were then grouped and prioritized using a point-based
voting system where each partner had one vote to rank the
importance of each question as high, medium or low. It is worth
noting that there were considerable differences in the rankings
between academic institutions from different domains (e.g. Uni-
versity of Vienna and Leiden University Medical Center), but
almost perfect correlation between EFPIA companies and aca-
demic institutions from the medicinal chemistry domain (e.g.
University of Vienna and AstraZeneca).
Prioritizing the 83 collected research questions and subsequent
analysis of the top 20 of these led to a deeper insight into the
actual information needs of researchers (in the pharma industry
as well as in academia and biotech) regarding data associations.
This analysis was carried out by extracting the key concepts
(compound, target, pathway, disease), as well as crucial mappings
between concepts implied in each question needed to start a
conventional data search. The application of this procedure
resulted in three main groups of 29 target/protein-related, 21
compound-related and 21 either disease- or pathway-related
questions. Minor groups from this analysis comprise gene/gene
family (six questions), substructure (five), protein family (three),
RNA (one) and assay (one).
To complete the above analysis and have an overview of what
requesters expect in highly ranked questions, we included for each
question the keywords compound, target, pathway and disease, in
each category of prioritization (Fig. 1). It immediately becomes
obvious that the concept ‘compound–target’ is predominantly
found in the highly prioritized questions. All questions contain
the concept ‘compound’, and 16 out of the top 20 questions also
refer to ‘target’. The top 20 questions were then grouped in two
clusters according to the complexity of information requested
about compound–target or compound–target–disease/pathway.
The questions and their clusters are summarized in Table 1, and
are herein analyzed in terms of required data concepts, required
data associations and potential public data sources needed.
Cluster I: compound–target
This first cluster contains 11 questions centered on basic pharma-
cology. These types of questions are usually asked in early drug
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discovery phases at the hit- or lead-finding stages. Generally, the
user wishes to find out more about known interactions between a
compound or a set of compounds and a defined primary target
and/or other targets. The request can be expanded toward a target
family and/or the same target in different species. By defining an
activity threshold, the user expects a list of compounds that can be
useful for direct screening or to provide input for compound
library design targeting a new enzyme, for instance an oxidore-
ductase (Q1, Table 1).
Although looking deceptively simple, this question is challen-
ging because it requires checking each compound for activity
against the >3000 oxidoreductases in both species concerned.
The question also illustrates the common approach of ‘target
families’ and hence highlights the need for a well maintained target
classification system. A manual search took two scientists three days
to retrieve the respective list of compounds. The prototype released
internally six months after the start of the project was able to
perform this query within a few seconds. Regarding information
on multiple targets or ADMET effects (Q2 and Q3, Table 1), ques-
tions are motivated by the need to understand the mechanism of
possible side-effects of drug candidates and drugs [17]. These are
typically asked when lead and drug candidates are assessed to decide
whether or not to progress them for further development. The
metabolism/toxicity-related issues could at least in part be answered
by providing predicted secondary pharmacology data for a given
compound of interest. The predicted data could be from an inter-
rogation of existing bioactivity data or based on predictive in silico
models as applied, for example, in the Chemotargets software for
predicting the off-target pharmacology of small molecules [18], the
SEA-approach [19] or the PASS algorithm [20].
In some cases the user might be more interested in a profile of
activity rather than a single activity or interested in similar com-
pounds with a similar activity profile (Q4 and Q9, Table 1). To
answer this type of question one has to provide a defined bioac-
tivity interaction profile, and then search for compounds that
share similarity in terms of their bioactivity profile. This use case
addresses a typical lead-finding strategy searching for compounds
with different chemotypes but similar bioactivity profiles that are
also expected to share activity on new targets [21]. In comparison
with previous questions the complexity increases remarkably
when the definition of the query requires substructure matching
capabilities and similarity searching (Q5 and Q10, Table 1). To
query and answer the specific questions above might well go
beyond the capabilities of a simple, easy-to-use graphical user
interface (GUI). Thus, a set of end-user applications, so called
example applications (eApps), are developed within the consor-
tium on top of a robust Open PHACTS services application pro-
gramming interface (API) and will be discussed later. These eApps
are proof-of-concept studies to demonstrate the capability of the
Open PHACTS discovery platform and API to enable effective
services built on top of it. They comprise tools with advanced
querying capabilities as well as scientific applications addressing
specialized needs.
To answer questions such as Q6 and Q8 (Table 1), a certain level
of granularity in the gene classification systems is needed. In fact,
the answer to Q6 returns a list of chemical compounds with
structures that are active against protein kinase C (PKC)a or all
other members of the PKC subfamily of kinases. The question is a
typical homology-based hit-finding strategy applicable for projects
where a large knowledge base exists [22]. The answer to Q8, where
specific interactions are targeted such protein–protein interactions
(PPIs), needs a specific database for such request. Finally, an answer
to Q11 requires late-phase development clinical data. The ques-
tion, motivated by the desire to assess clinical compounds, can be
part of both clusters because the clinical data can be linked to a
disease study. For the specified list of clinical compounds, the
system should provide the available clinical data in addition to the
bioactivity data. However, although incredibly useful, this is
beyond the reach of the Open PHACTS project in its current
definition. Nevertheless, the integration capabilities offered by
the Open PHACTS discovery platform definitely will allow exten-
sions toward translational data.
Cluster II: compound–target–disease/pathway
The second cluster contains nine questions that deal with the
previous concepts of compound–target relationships but, in addi-
tion, information about more-complex pharmacology in context
of pathways and diseases is needed. The information requested in
most of the cases needs references associated with it (patents,
journal articles). These types of questions are usually asked during
the lead optimization phase or proof-of-concept studies. The first
question in the cluster (Q12, Table 1) is motivated by the fact that
patents constitute an indispensable information source for che-
mical compounds and biological targets. The complexity of the
question is twofold: first, all patents have to be retrieved that relate
to the compound and the disease of interest; in a second step, the
targets need to be extracted from the patent claims. However, the
retrieval and/or tagging of text [23], as well as the recognition of
targets within patents [24], is extremely challenging and subject to
active research.
Question 13 (Table 1) is an aggregate of different questions seen
already; owing to its composite nature the complexity is extremely
high. First, as in Q3, the bioactivity of a compound for a specific
target needs to be established. As in Q11, the compound is in
preclinical or clinical phase and is an advanced compound
that should have public data available. The link to the relevant
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FIGURE 1
The percentage of the 83 questions with respect to the key words:
compound, target, pathway, disease; categorized by priorities. It clearly
demonstrates that the concepts ‘compound’ and ‘target’ are the most
dominant.
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publications and patents renders it similar to Q12 and Q17. The
compound–publication and target–publication associations are
needed. In some questions such as Q14 there is a need to compare
the resulting data with proprietary in-house data, which poses a
technical challenge because the publicly available Open PHACTS
discovery platform needs to be able to integrate proprietary data.
This imposes another level of complexity because it requires secure
access. In addition, the whole issue of licensing needs to be
addressed, which is extremely demanding when it comes to mix-
ing public and private data into one platform.
Question 15 can be related to Q5 and Q10. However, what is
new in regard to the related questions is the specification of the
concept of a chemical series; hit compounds would need to be
clustered around the parent series scaffold. Although various
computational definitions for this task exist, there still remains
the challenge of agreeing on the method to be used in the first
instance. Open PHACTS is thus also actively working on providing
standards agreed and widely adopted by the community, also
including the pharmaceutical industry. Finally, the question of
new targets associated with a disease and the competitive land-
scape around a target or disease are factors interrogated in Q15.
Questions 17 and 18 are similar to Q3. More specifically, they
require the knowledge of the pathway(s) where the specific target
is representing a node. The capability to extract the upstream and
downstream interaction partners from the pathway map adds an
extra degree of complexity. Answering Q19 and Q20 imposes two
levels of complexity. First, the compounds that hit the known
targets in a given canonical disease pathway would need to be
identified. In a second step, the most-specific compounds would
need to be extracted. Both questions are relevant in the context of
target and lead identification in the newer biology-driven drug
discovery paradigm [25,26].
Data association and/or data sources
The analysis of the scientific competency questions demonstrates
that the data and associations between the concepts ‘chemical
compound’, ‘molecular target’, ‘biological pathway’ and ‘disease’
are essential to address the questions. One can visualize the com-
plexity of the data associations in a network fashion (Fig. 2). With
this network, we intend to summarize the data and associations
needed to answer just the top 20 prioritized questions and thus to
lay the foundation for selecting public databases that provide the
respective information. In this section we will go through the
details of the data needed and the public databases that provide
such data (details and references about the data sources are listed
in Table 2).
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The top 20 research questions
Question number Question
Cluster I
Q1 Give me all oxidoreductase inhibitors active <100 nM in human and mouse
Q2 Given compound X, what is its predicted secondary pharmacology? What are the on- and off-target safety concerns for a
compound? What is the evidence and how reliable is that evidence (journal impact factor, KOL) for findings associated with
a compound?
Q3 Given a target, find me all actives against that target. Find/predict polypharmacology of actives. Determine ADMET profile
of actives
Q4 For a given interaction profile – give me similar compounds
Q5 The current Factor Xa lead series is characterized by substructure X. Retrieve all bioactivity data in serine protease assays
for molecules that contain substructure X
Q6 A project is considering protein kinase C alpha (PRKCA) as a target. What are all the compounds known to modulate the
target directly? What are the compounds that could modulate the target directly? I.e. return all compounds active in assays
where the resolution is at least at the level of the target family (i.e. PKC) from structured assay databases and the literature
Q7 Give me all active compounds on a given target with the relevant assay data
Q8 Identify all known protein–protein interaction inhibitors
Q9 For a given compound, give me the interaction profile with targets
Q10 For a given compound, summarize all ‘similar compounds’ and their activities
Q11 Retrieve all experimental and clinical data for a given list of compounds defined by their chemical structure (with options
to match stereochemistry or not)
Cluster II
Q12 For my given compound, which targets have been patented in the context of Alzheimer’s disease?
Q13 Which ligands have been described for a particular target associated with transthyretin-related amyloidosis, what is their
affinity for that target and how far are they advanced into preclinical/clinical phases, with links to publications/patents
describing these interactions?
Q14 Target druggability: compounds directed against target X have been tested in which indications? Which new targets have
appeared recently in the patent literature for a disease? Has the target been screened against in AZ before? What
information on in vitro or in vivo screens has already been performed on a compound?
Q15 Which chemical series have been shown to be active against target X? Which new targets have been associated with
disease Y? Which companies are working on target X or disease Y?
Q16 Which compounds are known to be activators of targets that relate to Parkinson’s disease or Alzheimer’s disease
Q17 For my specific target, which active compounds have been reported in the literature? What is also known about upstream
and downstream targets?
Q18 Compounds that agonize targets in pathway X assayed in only functional assays with a potency <1 mM
Q19 Give me the compound(s) that hit most specifically the multiple targets in a given pathway (disease)
Q20 For a given disease/indication, give me all targets in the pathway and all active compounds hitting them
846 www.drugdiscoverytoday.com
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Chemistry node
The information about drug names and the required search mode
depends strongly on the use of correct chemical names such as
systematic names, trade names or synonyms. Such dictionaries of
chemical name–structure associations are available from a number
of chemical databases including ChEBI, DrugBank and ChemSpi-
der [27]. In addition, chemical structure information is needed for
defining queries such as substructure matching or similarity
searches. This point stresses the need for data quality in general
and especially on the exactness of representation of chemical
structures, including stereochemistry, tautomers and protonation
states. The quality of data in public domain databases has been
discussed in a number of publications and highlights the need for a
consistent and publicly described framework for normalization
[28,29]. Within the Open PHACTS project those chemical-related
queries will be provided via an interface to the ChemSpider
molecular information system. For the compound–bioactivity
association several highly popular databases will be integrated
in the Open PHACTS discovery platform. In the first instance,
those are ChEMBL, Chebi and DrugBank, which comprise large-
scale public sources for the compound and bioactivity data. The
bioactivity databases provide data at the level of primary activity at
a single concentration of compound or data from dose–response-
based experiments such as IC50 and/or EC50, Ki or Kb. Hence, there
is a need for the system to handle quantitative data within the
semantic interoperability framework.
Biology nodes
It is important to recognize that a target in a given assay can be of
heterogeneous nature, including proteins, cells or even whole
organisms. To illustrate this, a search performed in ChEMBL for
propafenone, a class 1C antiarrhythmic agent, revealed target
name instances such as Ratus norwegicus, Plasmodium falciparum,
CYP 450 2D6 and CCRF CEM 1000. It is thus necessary to represent
the target–protein–gene associations in full detail. The gene–phe-
notype association can be found in the OMIM or GO data systems.
More specifically, gene–side-effect associations can be found in
specific literature on safety profiling [17]. The IUPHAR database
provides structured pharmacological data on ion channels, G-
protein-coupled receptors (GPCRs) and nuclear receptors. The
SIDER database at EMBL contains information on marketed med-
icines and their recorded adverse drug reactions. However, it
should be mentioned that the definition of secondary pharmaco-
logical data is ‘fuzzy’ given that a compound can have more than
one primary target in the view of its polypharmacology, which
finally defines its pharmacodynamic in vivo profile [30].
Protein–pathway association data are provided by the WikiPath-
ways and Reactome data repositories. Also the GO classification of
genes will be useful in this context. Gene–disease association data
are part of the OMIM and Diseaseome datasets. This nicely illus-
trates the need for granularity in the gene classification systems.
Because the previously explored target families such target ontol-
ogies have been elaborated [31]. The key difficulty is to have
Drug Discovery Today  Volume 18, Numbers 17/18  September 2013 REVIEWS
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FIGURE 2
Network of data associations needed to answer the top-ranked scientific competency questions. The network reflects a cartoon that summarizes the data
associations that are needed to target the top 20 research questions.
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TABLE 2
Summary view of data sources, content and data concepts that are of interest for an open pharmacological space, recorded in March
2012. Emphasized is the open and free public access of the data sources
Database name Internet resource URL/source Specification of data and information available
ADME-AP http://bioinf.xmu.edu.cn/databases/
pathways/ADMEAP.htm
ADME-AP provides comprehensive information about all classes of ADME-associated
proteins described in the literature including physiological function of each protein,
pharmacokinetic effect, ADME classification, direction and driving force of disposition,
location and tissue distribution, substrates, synonyms, gene name and protein
availability in other species. Cross-links to other databases are also provided to facilitate
the access of information about the sequence, 3D structure, function, polymorphisms,
genetic disorders, nomenclature, ligand binding properties and related literatures of
each protein. ADME-AP currently contains entries for 321 proteins and 964 substrates
Cancer Central Clinical
Database (C3D)
https://cabig.nci.nih.gov/community/
tools/c3d
C3D is a clinical trials data management system that collects clinical trial data using
standard case report forms based on common data elements. It utilizes security
procedures to protect patient confidentiality and maintain an audit trail as required by
FDA regulations
ChEBI http://www.ebi.ac.uk/chebi/ ChEBI (Chemical Entities of Biological Interest) is a freely available dictionary of chemical
compounds, with IUPAC and NC-IUBMB endorsed terminology. Currently three data
sources have been incorporated into ChEBI, namely KEGG Ligand, IntEnz and Chemical
Ontology
ChemBank http://chembank.broadinstitute.org/ ChemBank is a freely available chemoinformatics database. The data are derived from
small molecules and small-molecule screens and resources for studying these data. It
was developed through a collaboration with the Chemical Biology Program and Platform
at the Broad Institute of Harvard and MIT
ChEMBL https://www.ebi.ac.uk/chembl/ ChEMBL is a database of bioactive drug-like small molecules. This database also contains
2D structures, calculated properties (e.g. log P, molecular weight, Lipinski parameters)
and abstracted bioactivities (e.g. binding constants, pharmacology and ADMET data)
ChemSpider http://www.chemspider.com/ ChemSpider is a free chemical structure database from the Royal Society of Chemistry
providing fast text and structure/substructure search access to over 26 million structures
from over 400 data sources
ClinicalTrials.gov http://clinicaltrials.gov/ ClinicalTrials.gov is a registry and results database of federally and privately supported
clinical trials conducted in the USA and around the world. It gives information about a
trial’s purpose, who may participate, locations and phone numbers, among others
Diseases Database http://www.diseasesdatabase.com/ The Diseases Database is a database that underlies a free website that provides
information about the relationships between medical conditions, symptoms and
medications
DISEASOME http://diseasome.kobic.re.kr/ DISEASOME provides the genes that are associated with diseases and potentially
deleterious SNPs among the genes that are strongly associated with specific diseases
and clinical phenotypes. Currently, it contains 14,674 records on genetic variation and
109,715 records on genes related to human diseases
DrugBank http://www.drugbank.ca/ The DrugBank database combines detailed drug (i.e. chemical, pharmacological and
pharmaceutical) data with comprehensive drug target (i.e. sequence, structure and
pathway) information. The database (version 3.0) contains 6708 drug entries. 4229
nonredundant protein (i.e. drug target/enzyme/transporter/carrier) sequences are linked
to these drug entries
GenBank http://www.ncbi.nlm.nih.gov/
genbank/
GenBank is the NIH genetic sequence database, an annotated collection of all publicly
available DNA
GO Database http://www.geneontology.org/ The GO (Gene Ontology) database is a relational database comprising the GO ontologies
and the annotations of genes and gene products to terms in the GO. The advantage of
housing the ontologies and annotations in a single database is that powerful queries can
be performed over annotations using the ontology
HMDB http://www.hmdb.ca/ The Human Metabolome Database (HMDB) is a freely available electronic database
containing detailed information about small molecule metabolites found in the human
body. The database (version 2.5) contains over 7900 metabolite entries. Additionally,
approximately 7200 protein (and DNA) sequences are linked to these metabolite entries
IntAct http://www.ebi.ac.uk/intact/ IntAct provides a freely available, open source database system and analysis tools for
protein interaction data. All interactions are derived from literature curation or direct
user submissions and are freely available
InterPro http://www.ebi.ac.uk/interpro/ InterPro is an integrated database of predictive protein signatures used for the
classification and automatic annotation of proteins and genomes. It classifies sequences
at superfamily, family and subfamily levels, predicting the occurrence of functional
domains, repeats and important sites. InterPro adds in-depth annotation, including GO
terms, to the protein signatures
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TABLE 2 (Continued )
Database name Internet resource URL/source Specification of data and information available
IUPHAR Database http://www.iuphar-db.org/ The IUPHAR Database is the official database of the IUPHAR Committee on Receptor
Nomenclature and Drug Classification. It incorporates detailed pharmacological,
functional and pathophysiological information on G-protein-coupled receptors, voltage-
gated ion channels, ligand-gated ion channels and nuclear hormone receptors
KDBI http://bidd.nus.edu.sg/group/
kdbi/kdbi.asp
Kinetic data of biomolecular interaction (KDBI) is a collection of experimentally
determined kinetic data of protein–protein, protein–RNA, protein–DNA, protein–ligand,
RNA–ligand, DNA–ligand-binding or reaction events described in the literature
MetaCyc http://metacyc.org/ MetaCyc is a database of nonredundant, experimentally elucidated metabolic pathways.
MetaCyc contains more than 1100 pathways from more than 1500 different organisms.
MetaCyc is curated from the scientific experimental literature and contains pathways
involved in primary and secondary metabolism, as well as associated compounds,
enzymes and genes
OMIM http://www.ncbi.nlm.nih.gov/
omim
OMIM (online Mendelian inheritance in man) is a comprehensive, authoritative and
timely compendium of human genes and genetic phenotypes. The full-text, referenced
overviews in OMIM contain information on all known Mendelian disorders and over
12,000 genes. OMIM focuses on the relationship between phenotype and genotype
2P2I http://2p2idb.cnrs-mrs.fr/ The 2P2I database stores structural information about PPIs with known inhibitors and
provides a useful tool for biologists to assess the potential druggability of their interfaces
PDSP http://pdsp.med.unc.edu/ PDSP (Psychoactive Drug Screening Program) provides screening of novel psychoactive
compounds for pharmacological and functional activity at cloned human or rodent CNS
receptors, channels and transporters
PharmGKB http://www.pharmgkb.org/ The PharmGKB database is a central repository for genetic, genomic, molecular and
cellular phenotype data and clinical information about people who have participated in
pharmacogenomics research studies. The data includes, but is not limited to, clinical and
basic pharmacokinetic and pharmacogenomic research in the cardiovascular,
pulmonary, cancer, pathways, metabolic and transporter domains
Protein Data Bank (PDB) http://www.rcsb.org/pdb/home/
home.do
The PDB archive contains information about experimentally determined structures of
proteins, nucleic acids and complex assemblies. Users can perform simple and advanced
searches based on annotations relating to sequence, structure and function
PubChem/PubMed http://pubchem.ncbi.nlm.nih.gov/
http://www.ncbi.nlm.nih.gov/
pubmed/
PubChem is a free database of small molecules and information on their biological
activities. The system is maintained by the National Center for Biotechnology
Information (NCBI), a component of the National Library of Medicine, which is part of the
United States National Institutes of Health (NIH). It is linked to NIH PubMed/Entrez
information
REACTOME http://www.reactome.org/
ReactomeGWT/entrypoint.html
REACTOME is an open source, open access, manually curated knowledgebase of
biological pathways in humans. Pathway annotations are authored by expert biologists,
in collaboration with Reactome editorial staff and cross-referenced to many
bioinformatics databases
SIDER http://sideeffects.embl.de/ SIDER (Side Effect Resource) contains information on marketed medicines and their
recorded adverse drug reactions. The information is extracted from public documents
and package inserts. The available information includes side-effect frequency, drug and
side-effect classifications as well as links to further information, for example drug–target
relationships
STITCH http://stitch.embl.de/ STITCH (search tool for interactions of chemicals) is a searchable database that integrates
information about interactions from metabolic pathways, crystal structures, binding
experiments and drug–target relationships. This database contains interactions for
between 300,000 small molecules and 2.6 million proteins from 1133 organisms
SUPERTARGET http://bioinf-apache.charite.de/
supertarget_v2/
SuperTarget is a database that contains more than 2500 target proteins, which are
annotated with about 7300 relationships to 1500 drugs; the vast majority of entries have
pointers to the respective literature source
TOXLINE http://toxnet.nlm.nih.gov/cgi-bin/
sis/htmlgen?TOXLINE
TOXLINE records provide bibliographic information covering the biochemical,
pharmacological, physiological and toxicological effects of drugs and other chemicals. It
contains over 4 million bibliographic citations, most with abstracts and/or indexing
terms and CAS registry numbers
UniProt http://www.ebi.ac.uk/uniprot/ UniProt is a freely accessible database of protein sequence and functional information,
many of it derived from genome sequencing projects. It contains a large amount of
information about the biological function of proteins derived from the research literature
WikiPathways http://wikipathways.org/index.php/
WikiPathways
WikiPathways is an open, collaborative platform dedicated to the curation of biological
pathways. It was built on the MediaWiki software and thus enables a broad usage by the
entire community
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ontologies at the genome-wide level, with the need for a sustained
development of ontologies for medicinal chemistry targets. This
further expands toward ontologies especially dealing with ADME
and toxicity. Because of its intrinsic complexity a toxicology
ontology represents a particular challenge and is addressed within
the IMI eTox Consortium [32]. Finally, to retrieve assay data not
only indirectly from databases but also directly from the primary
literature poses an immense challenge for chemical and biological
text mining [33–35]. Some specific questions were related to PPIs,
which again stresses the need for granularity in the gene classifica-
tion systems. With the 2P2I database a specific data source regard-
ing PPI inhibitors is emerging. The value of PPI datasets such as
IntAct would need to be evaluated in the perspective of its rele-
vance to contribute to the answer for Q8. One of the highest-
prioritized questions was related to oxidoreductase enzymes. In
this case, the Enzyme Commission (EC) classification system in
UniProt provides a source for the enzyme classification.
Patent and publication node
Patents constitute a valuable source of information for chemical
compounds and biological targets. To answer some of the ques-
tions related to patents, all patents that relate to the compound
and the disease of interest have to be retrieved. In a second step,
the targets need to be extracted from the patent claims. Currently,
no public domain database with the required specific data associa-
tions exists. The European Bioinformatics Institute (EBI) in colla-
boration with the European Patent Office (EPO) is working toward
this goal [36]. Also, the SureChem family of products [37] offers
access to a comprehensive international patent collection, which
is normalized and curated. Finally, the IBM patent analytics plat-
form is a pharmaceutical industry consortium focusing on the
same area [38,39]. However, accurate extraction of chemical struc-
ture information from patent documents constitutes a key chal-
lenge [40], which needs considerable attention. With respect to
publications, the most popular public database used to access
references of publications is PubMed. Although target and chemi-
cal names can be directly extracted from abstracts, extracting all
chemicals in a publication with its associated data will certainly
remain a significant challenge.
Finally, it has to be pointed out that the main goal of Open
PHACTS – connecting publicly available databases – inherently
puts a ‘data bias’ onto the whole system. In addition, the selection
of data sources is also heavily influenced by their respective
license. Thus, although some data sources can be better than
others, the final choice is based on a list of criteria rather than
on best coverage of the respective domain. These include, among
others, the compatibility of the license with the Open PHACTS
license, the availability of an RDF version, regular updates and
maintenance, and data quality.
OPS example end-user applications (eApps)
The Open PHACTS infrastructure will consist of a series of software
components that together form a platform that multiple applica-
tions can be built upon. All applications access the underlying data
via an API that provides access to optimized queries of the system.
Form-based queries within the core Open PHACTS interface (Open
PHACTS explorer) will enable the bench scientist to address key
use cases like the retrieval of compound, target and pathway
information. In addition to the API, several other end-user appli-
cations will be co-developed with the Open PHACTS discovery
platform, such as a target dossier, a polypharmacology browser, a
chembio navigator and an application specialized for linking to
the toxicity data store established under the framework of the eTox
project. The relevance of these tools is not only to show how it is
possible to build relevant end-user applications on top of the core
platform but also to provide the bench scientist with immediate
value. The target dossier is designed to provide a comprehensive
view on pharmacologically relevant targets to answer questions
regarding druggability, tissue expression profiles and implications
in pathways, disease states and physiological mechanisms. The
polypharmacology browser is a tool that aims at enabling scientists
to define a target profile of interest and interrogate the Open
PHACTS discovery platform for compounds having affinity for
some or all of those targets, as well as for additional proteins that
might show a degree of cross-pharmacology with any of the targets
in the profile. The chembio navigator will enable intuitive brows-
ing of the chemical and biological spaces. With filtering by various
structure and physicochemical descriptors, as well as by chemical
substructure and bioactivity data, the chembio navigator enables
an interactive analysis of datasets. Connected to the Open
PHACTS discovery platform, it will enable the user to drill down
into the primary data via hyperlinks.
Challenges
Heterogeneity of data and chemical data integration
When integrating databases of different origin and built on dif-
ferent concepts (compound, target, pathway, disease, among
others), the heterogeneous nature of the data needs to be empha-
sized, as does the diverse nature of the quality of data contained in
the various databases. This poses a significant challenge to their
integration within the framework of more-classical relational
databases, especially for compound databases where the mappings
between chemical compounds are generally based on an electronic
structure format such as molfiles, SMILES and InChIs [41]. Indeed,
currently there is no public information system available that is
based on the relational database model and that allows the type of
more complex competency questions posed here to be addressed.
The majority of existing information systems has succeeded in
integrating associations between pairs of the above mentioned
data concepts. The ChEMBL system for instance provides an
excellent integration of the compound–target concepts including
an ontology for the represented targets. Also, within pharmaceu-
tical companies, large-scale integration of chemical structure and
bioactivity data – the SAR estate – has been successfully completed.
AstraZeneca, for instance, reported recently the development of a
relational enterprise application containing 45 million unique
chemical structures from 18 internal and external sources [42].
The system merges compound-to-assay-to-result-to-target rela-
tionships enabling users to search with drug names, synonyms,
chemical structures, patent numbers and target protein identifiers,
at a scale not previously available. Similarly, the ChemSpider
database has mapped together 26 million chemical structures from
over 400 distinct data sources, mostly available online, and pro-
vides links out to PubChem (where assay information can be
accessed), to Google Scholar and Pubmed (where articles can be
accessed) and to Google Patents and the SureChem patent service
REVIEWS Drug Discovery Today  Volume 18, Numbers 17/18  September 2013
850 www.drugdiscoverytoday.com
R
eview
s
IN
F
O
R
M
A
T
IC
S
where patents can be retrieved. ChemSpider also has links out to
the ligands on Protein Data Bank, and to the majority of the
compound-based databases mentioned in this article including
ChEBI, ChEMBL, DrugBank and HMDB. The handling of complex
chemical queries such as structure-, substructure- and similarity-
based searching for the Open PHACTS discovery platform will be
handled by accessing web services provided by the ChemSpider
database. ChemSpider holds the role of compound-based data
aggregator for the project and brings together compound-based
datasets, providing the appropriate database mappings to the
triple store, and uses stringent controls for data processing and
validation to ensure as high a quality as possible at the compound
level. Crowdsourcing capabilities are available on the platform so
that new compound data can be deposited and existing data can be
annotated and curated. ChemSpider contributes a subset of the
entire dataset available to the core platform. The data slice coin-
cides with the data sources identified to be of value to the Open
PHACTS project and includes ChEBI, ChEMBL and DrugBank,
together with ChemSpider identifier mappings, chemical names
and synonyms and structure representations including SMILEs
and InChIs. On the basis of feedback from the EFPIA members
of the Open PHACTS consortium, and in alignment with chemical
compound standardization recommendations from the FDA [43],
the ChemSpider database will be re-standardized in the near future
to ensure compatibility between FDA standards and the Open
PHACTS discovery platform. However, although all these success-
ful efforts demonstrate that it is indeed possible to bring together
the majority of the relevant chemical space, significant issues
remain, such as synchronized updates and maintaining integrity
of links, quality control of the chemical structures and, last but not
least, the big issue of normalization and standardization of che-
mical structures. The latter comprises protonation states, salts and
tautomers.
Further databases and need for ontologies
The focus aim of the Open PHACTS project is to cover the four
high-priority data concepts: chemical compound, molecular tar-
get, biological pathway and disease, including the relevant ontol-
ogies. Via mappings of identifiers, the semantic approach opens a
model-free approach for integration [44]. The data model is
included in the data and, in principle, no further specification
is needed. An explicit data model, as implied in relational data-
bases, restricts the query capabilities. Thus, Open PHACTS fosters
the reutilization and integration of the large public investment in
data sources rather than generation of additional databases.
Although the concepts ‘chemical compound’, ‘biological target’
and ‘biological pathway’ reference databases are well established,
relatively few data sources can be found around the concepts
‘disease/phenotype’. The development of public mechanistically
determined clinical trial data sources are thus further encouraged
and will help to advance application in translational medicine
[45]. In addition, several other IMI projects, such as eTRIX,
DDMORE and EHR4CR, are focusing on this area. A typical appli-
cation would be, for instance, the systematic repurposing of
marketed and experimental therapeutics by enabling the discov-
ery of new potential therapeutic indications [46,47]. In early drug
discovery, the development of databases of microscopic cell and
organism phenotype data as generated in high-content screening
(HCS) will potentially enable further closing of the gap between
molecular and physiological observations. A large number of
phenotypic compound screens are ‘black box’ screens where the
identification of active compounds needs to be followed-up by in
silico and in vitro chemogenomics target fishing approaches to
elucidate their possible mechanisms of action. Although there is
no concrete scientific competency question for this among the top
20 questions, many of them would be part of an HCS work-up
workflow. The analysis of the scientific competency questions also
demonstrates the need for further development of ontologies.
Ontologies are computable formal explicit specifications of a
shared concept of a knowledge domain. They define entities
and the relationships between these entities and express this
knowledge in a formal and computable way. These ontologies
and classifications are indeed essential to allow not only data
aggregation and navigation but also inference-based modeling.
In the perspective of medicinal-chemistry-driven applications
as outlined in the scientific competency questions, comprehensive
target and ADME ontologies are of the utmost importance, as is the
contribution of ADME data to the public domain [48]. The GO
classifications enable interesting aggregations for chemical biol-
ogy applications such as providing known compounds active
through a given biological mechanism like apoptosis or autop-
hagy. The InterPro classification enables the aggregation of data
for a given protein domain type. The ChEBI ontology [49,50]
provides a chemical information ontology that enables aggrega-
tion of compound classes like lipids (or many others), and was
established to provide biologists with a more intuitive access to the
chemical space. Finally, as outlined above, ChemSpider allows
large-scale chemistry integration and also aims at providing high-
quality chemical compound standardization.
Concluding remarks
The top 20 priority questions presented herein are prevalently
motivated by chemogenomics and chemical biology applications
that are essential to the early drug discovery process. They refer to
the basic concepts of compound–target and compound–target–
disease/pathway relationships. Other questions are motivated by
the more general scientific need to enable integrative assessment
of information on compounds, targets, pathways and diseases. The
first examples of such capabilities were provided by the Wild group
using their semantic system to investigate the genetic basis of side-
effects of thiazolinedione drugs, resulting in a hypothesis for the
recently discovered cardiac side-effects of rosiglitazone (Avandia1)
and a prediction for pioglitazone, which is backed up by recent
clinical studies [51]. These scientific motivations are also well
aligned with the overall goal of the Open PHACTS project to
deliver an open, integrated and sustainable chemistry, biology
and pharmacology resource for drug discovery. The openness of
the system for profit-based and non-profit-based organizations, as
well as the long-term sustainability plan for the Open PHACTS
discovery platform and API, will be crucial to its success in indus-
trial and academic drug discovery.
The functional Open PHACTS discovery platform will enable
the retrieval of existing data and associations. Given the complex-
ity of biological data, critical analysis by the end-user scientist will
be needed to interpret the findings appropriately. This critical
assessment will be especially important for the inferred knowledge
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that is enabled by the semantic rule-set and inference technolo-
gies. In addition, with the enormous progress in modern biology,
computational scientists are confronted with the need for flexible
integration of a wide source of data, which requires new
approaches. Finally, the concepts and technological solutions
outlined and pursued for the open pharmacological space could
be easily expanded to create an ecosystem of interoperable open
spaces [open transcriptomic space (OTS), open genomic space
(OGS): generally OXS] in the life science area.
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